Advances in Heart Failure with Preserved Ejection Fraction Management - The Role of Sacubitril-Valsartan, Pirfenidone, Spironolactone and Empagliflozin: Is Success a Series of Small Victories?

Background: Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterized by marked heterogeneity in comorbidities and etiopathology substrates, leading to a diverse range of clinical manifestations and courses. Treatment options have been extremely limited and up to this day, there are virtually no pharmaceutical agents proven to reduce mortality in these patients.

Objective: The primary objective of this narrative review is to critically summarize existing evidence regarding the use of Angiotensin Receptor-Neprilysin Inhibitor (ARNI), spironolactone, pirfenidone and empagliflozin in HFpEF.

Efficient syncope prediction from resting state clinical data using wavelet bispectrum and multilayer perceptron neural network.

Neurally mediated syncope (NMS) is the most common type of syncope, and head up tilt test (HUTT) is, so far, the most appropriate tool to identify NMS. In this work, an effort to predict the NMS before performing the HUTT is attempted. To achieve this, the heart rate variability (HRV) at rest and during the first minutes of tilting position during HUTT was analyzed using both time and frequency domains.